Denali Capital Acquisition Corp. (DECAW) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
437 MADISON AVENUE NEW YORK, NY 10022 |
| State of Incorp. | |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) (USD)
| 9/30/2024 MRQ | 12/31/2023 | 12/31/2022 | |||
|---|---|---|---|---|---|
| ASSETS | |||||
| Current Assets | |||||
| Cash, cash equivalents, and short-term investments | 204,464 | 819,747 | |||
| Cash and cash equivalent | 204,464 | 819,747 | |||
| Prepaid expense | 4,976 | 88,089 | |||
| Total current assets: | 209,440 | 907,836 | |||
| Noncurrent Assets | |||||
| Asset, held-in-trust | 50,477,963 | 85,371,600 | |||
| Total noncurrent assets: | 50,477,963 | 85,371,600 | |||
| TOTAL ASSETS: | 50,687,403 | 86,279,436 | |||
| LIABILITIES AND EQUITY | |||||
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities, including: | 18,878 | 1,291,641 | |||
| Accrued liabilities | 18,878 | ||||
| Other undisclosed accounts payable and accrued liabilities | 1,291,641 | ||||
| Debt | 975,000 | ||||
| Other undisclosed current liabilities | 4,610,102 | ||||
| Total current liabilities: | 5,603,980 | 1,291,641 | |||
| Noncurrent Liabilities | |||||
| Other undisclosed noncurrent liabilities | 2,887,500 | 2,887,500 | |||
| Total noncurrent liabilities: | 2,887,500 | 2,887,500 | |||
| Total liabilities: | 8,491,480 | 4,179,141 | |||
| Temporary equity, including noncontrolling interest | 50,477,963 | 85,371,600 | |||
| Equity | |||||
| Equity, attributable to parent, including: | (8,282,040) | (3,271,305) | |||
| Accumulated deficit | (8,282,297) | (3,271,562) | |||
| Other undisclosed equity, attributable to parent | 257 | 257 | |||
| Total equity: | (8,282,040) | (3,271,305) | |||
| TOTAL LIABILITIES AND EQUITY: | 50,687,403 | 86,279,436 | |||
Income Statement (P&L) (USD)
| 9/30/2024 TTM | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|
| Operating expenses | (3,173,826) | |||
| Operating loss: | (3,173,826) | |||
| Nonoperating income (Investment Income, Nonoperating) | 3,843,271 | 1,221,600 | ||
| Interest and debt expense | (36,909) | |||
| Net income: | 632,536 | 1,221,600 | ||
| Other undisclosed net loss attributable to parent | (1,640,990) | |||
| Net income (loss) attributable to parent: | 632,536 | (419,390) | ||
| Preferred stock dividends and other adjustments | (16,111,536) | |||
| Other undisclosed net loss available to common stockholders, basic | ||||
| Net income (loss) available to common stockholders, diluted: | 632,536 | (16,530,926) | ||
Comprehensive Income (USD)
| 9/30/2024 TTM | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|
| Net income: | 632,536 | 1,221,600 | ||
| Comprehensive income, net of tax, attributable to parent: | 632,536 | 1,221,600 | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.